Scancell founder says the company is ready to commercialise novel medicines to counteract cancer. Watch the video here.
Oof, thats another big number, Billy! I think RF are probably waiting to see if the run up to the AGM brings any thing in. I've been buying small traches since the RF news was announce. 5k shares in total. I know this will confuse those who think you should only have one view but my answer to that is 737. I now have 55k shares and these new 5000 shares are my trading pot that I will sell on a spike and 737 could be the next big spike. If not the p1b data readout should see us spike.
I'm thinking the same. 20k sells a day is 20 weeks to get rid of the first tranche. I know some days there were more than that but we are also assuming all big sells were RF. We're on week 17 or 18 too. I think they have some left plus the new ones.
If they have sold all 2 mil of the first tranche, they won't be anywhere near recouping their cash yet. Most of them were sold under 80p the 70p. They might wait for an AGM type boost and sell into that but IMO, this tranche they just been given will be offloaded before the Feb tranche is due. Then we'll need to give them some more to break even, then more to profit. It's weighted in their favour. I think we will be diluted by 5 million shares by the time the RF facility is settled. Hopefully, It will be worth it.
I'd never heard of RF until they got involved with Sareum but instead of shooting the messenger, I went off to see if the messenger was telling the truth. It turns out they were. 737 keeps me invested here and that's that.
MUST ONLY HAVE ONE VIEW. done in a Darlek voice.
My view,
Science = good
Boards ability to protect shareholder value = bad.
I don't come here for a hug. I come here to learn something that I dont know. I might even setup a Google alert for RF financing RNS's and short them. Seems like a dead cert.
Aber, I am resigned to the fact that it will get worse before it will get better. The RF facility is finance, pure and simple so RF won't know anymore than we do otherwise insider trading rules will have been broken. They may speculate and wait before selling but as the facility is weighted so they can't lose, they don't have to. I think they will start selling in the run up to the AGM and with another 300k tranche to drawdown in Feb 24. The facility will need be settled or we will have to give them more shares until it is. The above is why I feel triggered when some here start calling the likes of Puma a maj liars, they are not liars, it's all there in the RNS. You might not like it but our board thought this was our best option. 🙄. I'm bullish on the science and will keep buying in small tranches but I can't pretend the RF facility is good for Sareum, it's not. To potential partners, It will look like a crutch for a failing company to lean on and IMO, it weakens our negotiating power. I'm hoping that 737 news comes along and it oays for p2 do we can be rid of RF for good.
Yes, but all thing bring equal. Same p1b and same p2b data. If that data brings in an offer of 4 billion at p2b data. What is the risk adjusted discount to takeout at 1b. Is it 90,70, 60%? For ease of calculation A 90% discount would be 400 million x 2 (1801/2) plus whatever our share of 737 is worth. I think RMM once covered this in one of his posts.
Bring private will have added to the value here. No need to report finances, or shareholders that deals are on the table would massively help with negotiations. Unfortunately for Sareum, everything is there in the open. The other side can see our financial statement and could ride it out until the board and shareholders are desperate. I'm hoping 737 news comes and it massively strengthens our position. If enough up front to fund up to 2b then we'll get our buyout.
Yes, private company. Says in the article that one of the options for funding was an ipo but they decided not to and they placed shares with existing investors.
Question got the science bods here. If sar p1b is equal to or better than Nimbus p1b, is the probability the same for p2b? And if yes, a question for any MA accountants. Based on a 4 billion valuation at 2b, what would the risk adjusted value be for a 1b buyout? I think the likes of RMM and other could have a good go at this one.
Big take away for me is they had multiple billion dollar terms to review. That means there are other pharmas out there who lost out to Takeda. And they still might want a Tyk2 or 2. The valuation on p2b data leaves some wiggle room for a 2 billion valuation here at the same stage. Will say it again though. The TO model disappears once a licence is announced. We could still get that 2 billion valuation on p2b data readout though. We'll just have to wait for it.
It'll be interesting what indication they choose for 1802. It'll be a cancer but the indication might point the way to who eventually takes it. The 1802 lupus thing is the reason why I think both compounds will go to the same pharma. One is immune the other, cancer but I guess they are similar enough to treat both. It would be a patent and legal nightmare if they went to seperate pharma. This is the main reason a buyout could still happen but the window is getting smaller. I think we will know by next summer.
Funnily enough. Prof Tom Noakes researched sodium intake for his book Waterlogged. Lots of science and trials cited. The evidence seems to contradict everything we think and have been told about hydration and sodium intake. It's aimed at endurance athletes but a good, if a little science heavy read.
I have 2 close friends that both reversed their type 2 diagnosis with diet alone. One did keto, the other, the banting diet. Both diet are ultra low carb. The banting diet is more scienced backed though. High fat, low carb. I looslt follow the banting method. The only carbs I eat are green veg, I eat butter, meat and full fat cheese. Beer is difficult which is why I say I loosely follow the diet. Any pre diabetic or those already type 2 should look up prof Tim Noakes research into this. The evidence is pretty compelling.